BioOutsource Expands ADC Characterization Capabilities
News Feb 19, 2014
BioOutsource Ltd. has amplified its position as a global leader in Antibody Drug Conjugates (ADC) characterisation and has announced a partnership with Glythera Ltd, an emerging biotechnology company based in Newcastle-upon-Tyne that specializes in the development of next generation biotherapeutics through the application of its proprietary linker and stable glycan technologies.
“Building on our position as a leader in biological characterization of monoclonal antibodies, ADC’s represent an exciting development which will enhance the performance of a wide range of therapeutic products. We are delighted to partner with Glythera to characterize their ADC product in development, as we believe it holds considerable promise,” commented BioOutsource CSO, Daniel Galbraith.
Chief Operating Officer at Glythera Dr David Simpson, highlighted the value of the collaboration, “we are delighted to have the opportunity to work with BioOutsource on their ADC characterization as it is an area where our linker technologies offer significant benefits. This partnership demonstrates recognition of these powerful capabilities and we look forward to working with BioOutsource on this exciting project.”
BioOutsource has also announced that it will be exhibiting at the World ADC Summit, 17-20 February in Frankfurt, in partnership with Aptuit, Glasgow, a pharmaceutical services company, and with support from Scottish Development International (SDI).
“We are eagerly anticipating exhibiting at the World ADC Summit in Frankfurt,” continued Dr. Galbraith. “In partnership with Aptuit and with generous support from Scottish Development International, we welcome the opportunity to demonstrate our expertise in ADC characterization.”